| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $521K | -28.8% | -49.5% |
| SG&A Expense | $1.2M | +8.1% | +5.4% |
| Operating Income | -$1.8M | +6.3% | +20.2% |
| Net Income | -$1.8M | +8.4% | +18.2% |
| EPS (Basic) | -$0.08 | +55.6% | +78.9% |
| EPS (Diluted) | -$0.08 | +55.6% | +78.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.6M | -22.1% | -11.5% |
| Current Assets | $5.0M | -17.5% | -10.8% |
| Total Assets | $5.7M | -16.8% | -15.7% |
| Current Liabilities | $1.2M | -4.6% | +39.3% |
| Total Liabilities | $1.2M | -4.6% | +39.3% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.2M | — | — |
| Investing Cash Flow | $150K | — | — |
| Financing Cash Flow | $5.9M | — | — |
| $4.5M |
| -19.4% |
| -23.4% |